We serve Chemical Name:(5,6-dimethoxypyridin-2-yl)methanamine CAS:1112850-40-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(5,6-dimethoxypyridin-2-yl)methanamine
CAS.NO:1112850-40-4
Synonyms:2,3-dimethoxy-6-aminomethylpyridine
Molecular Formula:C8H12N2O2
Molecular Weight:168.19300
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:57.37000
Exact Mass:168.09000
LogP:1.25780
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,3-dimethoxy-6-aminomethylpyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,3-dimethoxy-6-aminomethylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-dimethoxy-6-aminomethylpyridine Use and application,2,3-dimethoxy-6-aminomethylpyridine technical grade,usp/ep/jp grade.
Related News: Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions. (5,6-dimethoxypyridin-2-yl)methanamine manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. (5,6-dimethoxypyridin-2-yl)methanamine supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. (5,6-dimethoxypyridin-2-yl)methanamine vendor Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. (5,6-dimethoxypyridin-2-yl)methanamine factory Same as Imbruvica’s original monotherapy use, the Venclexta combo offers a convenient oral treatment, while the drug’s two other approved cocktails—with Gazyva or Roche’s Rituxan—involve infusions.
